Operator: Good day, everyone, and welcome to the Syndax Third Quarter 2025 Earnings Conference Call. Today’s call is being recorded. [Operator Instructions]
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
—
**Sharon Klahre**
*Vice President of Investor Relations & Communications*  
Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax’s Third Quarter 2025 financial and operating results. I’m Sharon Klahre.
With me this afternoon to provide an update on the company’s progress and discuss financial results are:
– Michael Metzger, Chief Executive Officer
– Steve Closter, Chief Commercial Officer
– Dr. Nick Botwood, Head of R&D and Chief Medical Officer
– Keith Goldan, Chief Financial Officer
Also joining us on the call today for the question-and-answer session are:
– Dr. Peter Ordentlich, Chief Scientific Officer
– Dr. Anjali Ganguli, Chief Strategy Officer
This call is accompanied by a slide deck that has been posted on the Investor Relations section of our website.
https://seekingalpha.com/article/4837167-syndax-pharmaceuticals-inc-sndx-q3-2025-earnings-call-transcript?source=feed_all_articles